Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes

NCT ID: NCT06293664

Last Updated: 2024-03-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-04
• Study Completion Date: 2024-04-04

Brief Summary

Alpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland. It acts as an agonist to the melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and disposal. This study aims to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus (T2DM).

Detailed Description

Pre-clinical studies in mice have shown improved glucose clearance with α-MSH infusion, particularly in skeletal muscle. Research has demonstrated that α-MSH improves glucose tolerance in healthy humans by promoting glucose uptake in skeletal muscle cells.

Therefore this study seeks to answer the question of whether alpha-MSH improves glucose tolerance in patients with T2DM. This will be addressed through measuring the impact of α-MSH infusion in patients with T2DM. The research involves a double-blinded, randomized, placebo-controlled crossover study.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: SCREENING
• Blinding Strategy: QUADRUPLE

Study Groups

α-MSH infusion

Pharmaceutical grade α-MSH will be dissolved in 0.9% saline containing 0.5% human albumin.

Group Type: EXPERIMENTAL

α-MSH infusion

Intervention Type: OTHER

Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

Saline infusion

Saline infusion: Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.

Group Type: PLACEBO_COMPARATOR

Placebo solutions

Intervention Type: OTHER

Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.

Interventions

α-MSH infusion

Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

Intervention Type: OTHER

Placebo solutions

Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• People with T2DM treated with oral or injectable medications which have been stable for 3 months, but not insulin therapy for type 2 diabetes.
• Stable body weight and HbA1c for at least 3 months
• The participant is capable of giving written informed consent
• The participant is able to read, comprehend and record information written in English

Exclusion Criteria

• Previous or current psychiatric diagnosis listed in DSM-V Axis 1.
• Significant current or past medical or psychiatric history that, in the opinion of the investigators, contraindicates their participation.
• History of type 1 diabetes mellitus.
• History of endocrine disorder.
• History of ischaemic heart disease, hypertension (current BP > 160/95 mmHg), heart failure, cardiac arrhythmia, peripheral vascular or cerebrovascular disease.
• History or presence of significant respiratory, gastrointestinal, hepatic, oncological, neurological or renal disease or other condition that in the opinion of the Investigators may affect participant safety or outcome measures.
• Unwillingness or inability to follow the procedures outlined in the protocol.
• History of sensitivity to any of the peptides, or components thereof, or a history of drug or other allergy that, in the opinion of the investigators, contraindicates their participation.
• Use of current regular prescription or over-the-counter medications that in the opinion of the Investigators may affect participant safety or outcome measures.
• Clinically significant abnormalities in screening electrocardiogram (ECG) or blood tests abnormalities which in the opinion of the study physician, is clinically significant and represents a safety risk.
• Current pregnancy or breast-feeding in female participants (the investigators would advise using contraception for the duration of the study).
• Pulse rate <40 or >100 beats per minute OR systolic blood pressure >160 and <100 and a diastolic blood pressure >95 and <50 in the semi-supine position.
• The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first experimental visit in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than 3 new investigational medicinal products within 12 months prior to the screening.
• Participants who have donated, or intend to donate, blood within three months before the screening visit or following study visit completion.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dasman Diabetes Institute

OTHER

Sponsor Role: lead

Responsible Party

Dr. Ebaa Al Ozairi

CMO

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Dasman Diabetes Institute

Kuwait City, , Kuwait

Site Status: RECRUITING

Countries

Kuwait

Central Contacts

Ebaa Al Ozairi, MD

Role: CONTACT

ebaa.alozairi@dasmaninstitute.org

(+965) 22242999 ext. 3111

Facility Contacts

Ebaa Al Ozairi, MD

Role: primary

Dalal Alsaeed, PhD

Role: backup

Other Identifiers

RAHM-2023-006

Identifier Type: -

Identifier Source: org_study_id